中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
21期
101-102
,共2页
瑞舒伐他汀%强化治疗%脑梗死%复发率%药品不良反应
瑞舒伐他汀%彊化治療%腦梗死%複髮率%藥品不良反應
서서벌타정%강화치료%뇌경사%복발솔%약품불량반응
rosuvastatin%intensified treatment%cerebral infarction%recurrence rate%adverse reaction
目的 评价瑞舒伐他汀强化治疗对脑梗死患者复发率的影响及安全性.方法 选择医院确诊脑梗死100例患者,随机均分为对照组和观察组,各50例.对照组患者仅应用阿托伐他汀进行治疗,观察组患者采用瑞舒伐他汀强化治疗.结果 观察组治疗后患者的总胆固醇为(3. 12 ± 0. 78)mmol/L、低密度脂蛋白胆固醇为(1. 48 ± 0. 46)mmol/L,显著低于对照组患者的(3. 94 ± 0. 79)mmol/L和(2. 39 ± 0. 94)mmol/L ( P<0. 05 );观察组患者心血管事件复发率2. 00%,明显低于对照组的30. 00% ( P<0. 05 );观察组患者内中膜厚度(1. 35 ± 0. 33)mm、斑块面积(12. 12 ± 3. 33)mm2 及斑块数量(1. 58 ± 0. 46)个,均明显少于对照组患者的(1. 49 ± 0. 39)mm,(14. 94 ± 3. 98)mm2,(1. 70 ± 0. 59)个( P<0. 05 );观察组不良反应发生率明显低于对照组( P<0. 05 ).结论 瑞舒伐他汀强化治疗可有效控制脑梗死复发,促进胆固醇和血浆低密度脂蛋白胆固醇下降,有助于颈动脉斑块面积和数量减少,且未发生严重不良反应,值得临床推广.
目的 評價瑞舒伐他汀彊化治療對腦梗死患者複髮率的影響及安全性.方法 選擇醫院確診腦梗死100例患者,隨機均分為對照組和觀察組,各50例.對照組患者僅應用阿託伐他汀進行治療,觀察組患者採用瑞舒伐他汀彊化治療.結果 觀察組治療後患者的總膽固醇為(3. 12 ± 0. 78)mmol/L、低密度脂蛋白膽固醇為(1. 48 ± 0. 46)mmol/L,顯著低于對照組患者的(3. 94 ± 0. 79)mmol/L和(2. 39 ± 0. 94)mmol/L ( P<0. 05 );觀察組患者心血管事件複髮率2. 00%,明顯低于對照組的30. 00% ( P<0. 05 );觀察組患者內中膜厚度(1. 35 ± 0. 33)mm、斑塊麵積(12. 12 ± 3. 33)mm2 及斑塊數量(1. 58 ± 0. 46)箇,均明顯少于對照組患者的(1. 49 ± 0. 39)mm,(14. 94 ± 3. 98)mm2,(1. 70 ± 0. 59)箇( P<0. 05 );觀察組不良反應髮生率明顯低于對照組( P<0. 05 ).結論 瑞舒伐他汀彊化治療可有效控製腦梗死複髮,促進膽固醇和血漿低密度脂蛋白膽固醇下降,有助于頸動脈斑塊麵積和數量減少,且未髮生嚴重不良反應,值得臨床推廣.
목적 평개서서벌타정강화치료대뇌경사환자복발솔적영향급안전성.방법 선택의원학진뇌경사100례환자,수궤균분위대조조화관찰조,각50례.대조조환자부응용아탁벌타정진행치료,관찰조환자채용서서벌타정강화치료.결과 관찰조치료후환자적총담고순위(3. 12 ± 0. 78)mmol/L、저밀도지단백담고순위(1. 48 ± 0. 46)mmol/L,현저저우대조조환자적(3. 94 ± 0. 79)mmol/L화(2. 39 ± 0. 94)mmol/L ( P<0. 05 );관찰조환자심혈관사건복발솔2. 00%,명현저우대조조적30. 00% ( P<0. 05 );관찰조환자내중막후도(1. 35 ± 0. 33)mm、반괴면적(12. 12 ± 3. 33)mm2 급반괴수량(1. 58 ± 0. 46)개,균명현소우대조조환자적(1. 49 ± 0. 39)mm,(14. 94 ± 3. 98)mm2,(1. 70 ± 0. 59)개( P<0. 05 );관찰조불량반응발생솔명현저우대조조( P<0. 05 ).결론 서서벌타정강화치료가유효공제뇌경사복발,촉진담고순화혈장저밀도지단백담고순하강,유조우경동맥반괴면적화수량감소,차미발생엄중불량반응,치득림상추엄.
Objective To investigate the effect of rosuvastatin intensified treatment on the recurrence rate of cerebral infarction patients and it safety. Methods 100 patients the diagnosed as cerebral infarction were randomly divided into the control group and the observa-tion group, 50 cases in each group. Patients in the control group were only given atorvastatin treatment, and the observation group used rosuvastatin intensified treatmentcation. Results After treatment, the TC of the observation group was ( 3. 12 ± 0. 78 ) mmol/L, LDL-C was ( 1. 48 ± 0. 46 ) mmol/L, which were significantly lower than ( 3. 94 ± 0. 79 ) mmol/L and ( 2. 39 ± 0. 94 ) mmol/L of the control group ( P < 0. 05 );the recurrent cardiovascular rate of the observation group was 2. 00%, which was significantly lower than 30. 00% of the control group ( P < 0. 05 );the MIT of the observation was ( 1. 35 ± 0. 33 ) mm, plaque area ( 12. 12 ± 3. 33 ) mm2, and the plaque num-ber of ( 1. 58 ± 0. 46 ) , which were significantly less than ( 1. 49 ± 0. 39 ) mm, ( 14. 94 ± 3. 98 ) and ( 1. 70 ± 0. 59 ) of the control group ( P < 0. 05 );the adverse reaction rate of the observation group was significantly lower than the control group ( P < 0. 05 ) . Conclusion Rosuvastatin intensified treatment can effectively control the recurrence of cerebral infarction, promote the decrease of TC and LDL-C, contribute to the decrease of carotid plaque area and volume, and has no severe adverse reaction, which is worthy of clinical promotion.
